$502.4 M

FPRX Mkt cap, 20-Sep-2018
Five Prime Therapeutics Net income (Q2, 2018)-54.4 M
Five Prime Therapeutics EBIT (Q2, 2018)-57.1 M
Five Prime Therapeutics Cash, 30-Jun-201852.8 M

Five Prime Therapeutics Income Statement

Annual

USDFY, 2013FY, 2016FY, 2017

R&D expense

94.1 b150.9 m

General and administrative expense

35.8 b40 m

Operating expense total

129.9 b190.9 m

EBIT

(29.4 m)(99.2 b)(151.4 m)

Interest income

2.5 b3 m

Pre tax profit

(96.7 b)(148.5 m)

Income tax expense

31 b(1.7 m)

Net Income

(28.9 m)(65.7 b)(150.2 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

13.3 m24.7 m18.3 b22.2 b23.9 b33.8 b41.7 m43.6 m76.9 m

General and administrative expense

4.6 m5.2 m8.6 b8.1 b9.1 b10.5 b9.4 m10.5 m20.3 m

Operating expense total

17.9 m29.9 m26.9 b30.3 b33 b44.2 b51.1 m52.4 b54 m97.2 m

EBIT

(11.6 m)(24.1 m)(20.4 b)(21.1 b)(26.4 b)(34.1 b)(43.3 m)(44.1 b)(21.5 m)(57.1 m)

Interest income

117 k107 k536 m646 m639 m668 m702 k1.2 m2.7 m

Pre tax profit

(19.9 b)(20.4 b)(25.7 b)(33.4 b)(42.6 m)(20.4 m)(54.5 m)

Income tax expense

6.8 b7.3 b6.3 b(1.7 m)

Net Income

(11.5 m)(24 m)(13 b)(13.1 b)(19.4 b)(33.4 b)(44.3 m)(43.3 b)(20.4 m)(54.5 m)

Five Prime Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.2 m15.3 m150 m7.7 m59.8 m

Accounts Receivable

Inventories

Current Assets

77.7 m151.3 m528.3 m440.1 m311.2 m

PP&E

3.7 m3.8 m4.5 m6.2 m30.8 m

Total Assets

81.8 m155.6 m548.3 m448.3 m344 m

Accounts Payable

348 k1.1 m1.9 m334 k2.2 m

Short-term debt

Current Liabilities

13.8 m19.8 m79.4 m38.7 m51 m

Long-term debt

Common Stock

17 k

Preferred Stock

Additional Paid-in Capital

209.6 m274.2 m372.6 m396.6 m421.3 m

Retained Earnings

(151.6 m)(189 m)60.6 m(5 m)(155.6 m)

Total Equity

58 m433.2 m391.6 m265.2 m

Financial Leverage

1.4 x1.3 x1.1 x1.3 x

Quarterly

USDQ3, 2017Q1, 2018Q2, 2018

Cash

65.9 m52.8 m

Current Assets

403 m363 m

PP&E

30.3 m30 m

Total Assets

436.7 m396.8 m

Accounts Payable

2.9 m1.8 m2.5 m

Current Liabilities

41.2 m30.2 m

Additional Paid-in Capital

537.4 m545.9 m

Retained Earnings

(174.6 m)(208.7 m)

Total Equity

362.2 m336.9 m

Financial Leverage

1.2 x1.2 x

Five Prime Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.9 m)(37.4 m)249.6 m(65.7 m)(150.2 m)

Depreciation and Amortization

1.7 m1.6 m1.7 m1.7 m2.5 m

Accounts Receivable

Inventories

Accounts Payable

(209 k)701 k798 k(1.6 m)1.9 m

Cash From Operating Activities

(25.3 m)15.3 m289.1 m(79.8 m)(112.2 m)

Purchases of PP&E

(807 k)(1.6 m)(2.4 m)(3 m)(4.9 m)

Cash From Investing Activities

(42.2 m)(69.4 m)(238.2 m)(53.7 m)

Cash From Financing Activities

64.3 m61.2 m83.8 m(8.9 m)(9.9 m)

Income Taxes Paid

11.4 m1.7 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.5 m)(24 m)(13 b)(13.1 b)(19.4 b)(33.4 b)(43.3 b)

Accounts Payable

3.8 m347 k767 k672 k904 k1.4 m1.6 m1 m654 k528 k807 k1.3 m2.9 m

Five Prime Therapeutics Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information